Encure Bio-Executive Team
Dr. Rajendran Jagathesh Chandra Bose, Ph.D
Co-Founder & CEO
- Dr. JC Bose brings over 15 years of experience in drug development, specializing in AI-driven drug discovery, small molecules, biologics, and translational research. He earned his Ph.D. in Biomedical Engineering from Chung-Ang University, Seoul, South Korea, where he also gained hands-on experience in stem cell biology and tissue engineering at CHA Biotech, Seoul. Additionally, he holds BPharm and MPharm degrees from India, where he is a Registered Pharmacist.
- Dr. Bose completed his postdoctoral research at Stanford University School of Medicine, specializing in cancer nanotechnology, under the mentorship of Prof. Ramasamy Paulmurugan. During his time at Stanford’s Molecular Imaging Program and the Canary Center for Early Cancer Detection, he trained extensively in diverse molecular imaging techniques. His research focused on developing innovative nanoformulation-based therapeutics and applying cutting-edge imaging technologies for early cancer detection and therapy.
- He further advanced his research by collaborating with Prof. Maria Kontaridis and Prof. Jason McCarthy at Masonic Medical Research Institute (MMRI), where he innovated novel drug delivery systems targeting cardiovascular and autoimmune disorders, leveraging precision medicine approaches to improve therapeutic outcomes.
- His extensive R&D research and management experience includes serving as Managing Director of R&D at Jurata Thin Film (USA) and holding key R&D positions at Serina Therapeutics (USA), Sanofi (India), and LG Life Sciences (South Korea), along with a scientific role at Secant Group (USA).
- His contributions to drug delivery systems, vaccine biologicals, and pharmaceutical R&D have driven pioneering advancements in the field.
- As Co-Founder and CEO of Encure Biotherapeutics, Dr. Bose is at the forefront of integrating AI and quantum mechanics to revolutionize drug discovery and development. His mission is to accelerate the creation of life-changing therapies that are more accessible, affordable, and effective, transforming healthcare and significantly improving patient outcomes globally.
Dr. Jason R. McCarthy, Ph.D
Co-Founder & Scientific Advisor
- Dr. Jason McCarthy brings over 25 years of expertise in drug delivery, nanomedicine, and molecular imaging, with a focus on advancing treatments for oncology, inflammatory diseases, and precision medicine. With a proven track record in translational research, he has made significant contributions to the development of innovative imaging agents and targeted drug delivery platforms.
- Dr. McCarthy holds a Ph.D. in Inorganic Chemistry from the University of Connecticut and completed his postdoctoral fellowship at the Center for Molecular Imaging Research at Massachusetts General Hospital. Currently, he serves as an Associate Professor and Scientific Operations Director at the Masonic Medical Research Institute (MMRI). He has also held esteemed faculty positions at Harvard Medical School, where he led groundbreaking research in molecular imaging and drug delivery technologies.
- His research focuses on harnessing nanomedicine to deliver mRNA and small molecules to specific tissues and cells, optimizing therapeutic efficacy while minimizing side effects. By combining advanced molecular imaging with targeted drug delivery, he addresses critical challenges in treating diseases such as cancer, cardiovascular conditions, neurological disorders, and autoimmune diseases.
- As a Co-Founder and Scientific Advisor at Encure Biotherapeutics, Dr. McCarthy plays a pivotal role in leveraging AI-driven drug discovery to accelerate the development of transformative therapies. His innovative approach to precision medicine is key to Encure's mission of revolutionizing biopharmaceutical development and delivering life-changing treatments to patients worldwide.
- We are honored to have Dr. McCarthy as a visionary leader, whose expertise continues to drive innovation and shape the future of healthcare at Encure Bio.
Dr. Maria Kontaridis. Ph.D
Co-Founder & Scientific Advisor
- Dr. Maria Kontaridis brings over 25 years of groundbreaking expertise in pharmacology, cardiovascular biology, rare disorders, and autoimmune diseases. As an internationally recognized leader in molecular signaling and translational sciences, she has made transformative contributions to the understanding of the Shp2 protein, with profound implications for targeted therapies.
- Dr. Kontaridis earned her Ph.D. in Pharmacology from Yale University and completed her postdoctoral training at Beth Israel Deaconess Medical Center. She currently serves as the Executive Director and Gordon K. Moe Professor and Chair of Biomedical Research and Translational Medicine at the Masonic Medical Research Institute (MMRI). In addition, she holds a part-time role as an Associate Professor of Medicine at Harvard Medical School, underscoring her commitment to advancing both research and education.
- Her research focuses on unraveling the molecular mechanisms underlying congenital heart disease, end-stage heart failure, and rare autoimmune disorders. By leveraging cutting-edge technologies — including induced pluripotent stem cells (iPSCs), genetically engineered mouse models, and advanced molecular biology techniques — she identifies novel therapeutic targets with the potential to revolutionize patient care.
- At Encure Biotherapeutics, Dr. Kontaridis plays a crucial role in integrating translational research with AI-powered drug discovery, accelerating the development of innovative therapies for complex and underserved diseases. Her deep expertise in disease modeling and precision medicine continues to shape the future of biotechnology, offering new hope for patients with critical unmet medical needs.
- We are proud to have Dr. Kontaridis as a visionary leader at Encure Bio, where her commitment to advancing healthcare aligns with our mission to transform lives through cutting-edge science.
Dr. Ramasamy Paul murgan, Ph.D
Scientific Advisor
- With over 25 years of expertise in molecular imaging, nanomedicine, and gene therapy, Dr. Ramasamy Paulmurugan is a distinguished leader in targeted drug delivery, RNA therapeutics, and cancer biology.
- He serves as a Professor (Research) in Radiology at Stanford University's Molecular Imaging Program, where he leads the Cellular Pathway Imaging Laboratory (CPIL). He is also an esteemed member of Stanford Bio-X, the Stanford Cancer Institute, and the Wu Tsai Neurosciences Institute, reflecting his multidisciplinary impact across oncology and neuroscience.
- Dr. Paulmurugan’s pioneering research focuses on developing innovative imaging assays to monitor cellular signaling processes in cancer. Utilizing cutting-edge techniques — including bioluminescence, fluorescence, PET, SPECT, and CT — his work provides critical insights into tumor microenvironments, advancing both diagnostic precision and therapeutic strategies.
- Renowned for his groundbreaking contributions to treating aggressive cancers such as triple-negative breast cancer, hepatocellular carcinoma, and glioblastoma multiforme, he has spearheaded the development of nanoformulations for miRNA and small molecule combination therapeutics, driving new possibilities in precision medicine. His extensive expertise in preclinical and translational oncology and neurology has significantly influenced the evolution of targeted therapies.
- At Encure Biotherapeutics, Dr. Paulmurugan plays a pivotal role in advancing AI-driven drug discovery and innovative drug delivery systems. His deep scientific insights and commitment to transforming cancer treatment guide the development of next-generation therapeutics aimed at improving patient outcomes.
- We are honored to have Dr. Paulmurugan as part of our team, contributing his visionary expertise to help Encure Bio redefine the future of biotechnology and revolutionize healthcare. Together, we remain dedicated to pushing the boundaries of science to improve lives.